18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY by 源��옱吏� et al.
RESEARCH ARTICLE
18F-Mefway PET Imaging of Serotonin 1A
Receptors in Humans: A Comparison with
18F-FCWAY
Jae Yong Choi1, Chul Hyoung Lyoo2, Jin Su Kim3, Kyeong Min Kim3, Jee Hae Kang4, Soo-
Hee Choi5, Jae-Jin Kim6, Young Hoon Ryu1*
1 Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine,
Seoul, Korea, 2 Department of Neurology, Gangnam Severance Hospital, Yonsei University College of
Medicine, Seoul, Korea, 3 Molecular Imaging Research Center, Korea Institute of Radiological and Medical
Sciences, Seoul, Korea, 4 Department of Chemistry and Biochemistry, Swarthmore College, 500 College
Avenue Swarthmore, PA, United States of America, 5 Department of Psychiatry and Institute of Human
Behavioral Sciences, Seoul National University College of Medicine, Seoul, Korea, 6 Department of Psychiatry
and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea
* ryuyh@yuhs.ac
Abstract
Introduction
The purpose of this research is to evaluate the prospects for the use of 4-(trans-18F-fluora-
nylmethyl)-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexane-1-
carboxamide (18F-Mefway) in comparison to 18F-trans-4-fluoro-N-2-[4-(2-methoxyphenyl)
piperazin-1-yl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide (18F-FCWAY) for the quantifica-
tion of 5-HT1A receptors in human subjects.
Method
Five healthy male controls were included for two positron emission tomography (PET) stud-
ies: 18F-FCWAY PET after the pretreatment with 500 mg of disulfiram and two months later,
18F-Mefway PET without disulfiram. Regional time-activity curves (TACs) were extracted
from nine cortical and subcortical regions in dynamic PET images. Using cerebellar cortex
without vermis as reference tissue, in vivo kinetics for both radioligands were compared
based on the distribution volume ratio (DVR) calculated by non-invasive Logan graphical
analysis and area under the curve ratio of the TACs (AUC ratio).
Result
Although the pattern of regional uptakes in the 18F-Mefway PET was similar to that of the
18F-FCWAY PET (highest in the hippocampus and lowest in the cerebellar cortex), the
amount of regional uptake in 18F-Mefway PET was almost half of that in 18F-FCWAY PET.
The skull uptake in 18F-Mefway PET was only 25% of that in 18F-FCWAY PET with disulfi-
ram pretreatment. The regional DVR values and AUC ratio values for 18F-Mefway were 17—
40% lower than those of 18F-FCWAY. In contrast to a small overestimation of DVR values
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by AUC ratio values (< 10%) in 18F-FCWAY PET, the overestimation bias of AUC ratio val-
ues was much higher (up to 21%) in 18F-Mefway PET.
Conclusion
As 18F-Mefway showed lower DVR values and greater overestimation bias of AUC ratio val-
ues, 18F-Mefway may appear less favorable than 18F-FCWAY. However, in contrast to
18F-FCWAY, the resistance to in vivo defluorination of 18F-Mefway obviates the need for the
use of a defluorination inhibitor. Thus, 18F-Mefway may be a good candidate PET radioli-
gand for 5-HT1A receptor imaging in human.
Introduction
Serotonin 1A (5-hydroxytryptamine, 5-HT1A) receptors in the central nervous system belong
to the G-protein coupled receptor family and play an important role in cognitive and emotion-
al functions. Growing evidence demonstrates that the changes in 5-HT1A receptor binding has
been strongly implicated in the etiology of mental illnesses such as depression [1,2], anxiety
[3,4] and schizophrenia [5]. Thereby, the necessity of in vivo molecular imaging markers for
5-HT1A receptors has been increasingly recognized [6,7].
Many radioligands for positron emission tomography (PET) imaging of 5-HT1A receptors
have been developed, the majority of which are structural analogues of N-[2-[4-(2-methoxy-
phenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY-100635), a
5-HT1A receptor antagonist with a highly selectivity and affinity [8]. Although extensive in-
vestigation has been performed to find effective PET radioligands in the last decades, only
three radioligands are being used studies in human subjects: [11C]WAY-100635, 18F-trans-
4-fluoro-N-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-(2-pyridyl)cyclohexanecarboxa-
mide (18F-FCWAY), and 4-18F-fluoranyl-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-
N-pyridin-2-ylbenzamide (18F-MPPF).
The 11C-based radioligands have an intrinsic limitation for clinical studies because their
short half-life of 20 min requires a expensive cyclotron in the proximity of PET imaging facili-
ties. Besides these currently available 11C-labelled radioligands, 18F-FCWAY showed consider-
able defluorination in vivo [9,10] and 18F-MPPF was susceptible to P-glycoprotein (P-gp)
[11,12]. In vivo defluorination hampers the exact quantification of 5-HT1A receptor binding
in superficial brain areas due to contamination from radioactivity in the skull. This defluorina-
tion in humans can be ameliorated by the pre-administration of disulfiram, resulting in im-
proved brain PET images. However, as the disulfiram is difficult to use in practice and
potentially neurotoxic [13,14], there are limitations in widespread use of disulfiram for clinical
study of 18F-FCWAY PET.
To overcome this defluorination problem, the Mukherjee group developed 4-(trans-18F-
fluoranylmethyl)-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohex-
ane-1-carboxamide (18F-Mefway). This radiotracer extends the carbon bond on the cyclohexyl
ring of 18F-FCWAY to strengthen metabolic stability in vivo (Fig. 1). 18F-Mefway showed high
affinity to the 5-HT1A receptors, excellent target-to-reference ratio, high-quality 5-HT1A specif-
ic images in the rhesus monkey even without disulfiram and favorable characteristics in human
subject including low test-retest variability[15–18]. Moreover, 18F-Mefway showed kinetic
properties, whole-body biodistribution, and dosimetry similar to [carbonyl-11C]WAY-100635
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[17]. Thus, in the present study we evaluated 18F-Mefway for the quantification of 5-HT1A re-
ceptors in comparison with 18F-FCWAY in human subjects.
Material and Methods
Ethic clearance
Five healthy male subjects (age = 27.6 ± 2.2 years) participated in this study. Participants were
screened using self-report questionnaires, including the Social Interaction Anxiety Scale [19],
Social Phobia Scale [19], Brief Version of the Fear of Negative Evaluation Scale [20], and Beck
Depression Inventory [21]. All participants were medication-naïve and had no history of psy-
chiatric disorder. Institutional Review Board of Gangnam Severance Hospital ethically ap-
proved this study. The individual in this study has given written informed consent.
Radiosynthesis
18F-FCWAY and 18F-Mefway were prepared as previously described [22,23]. Specific activities
at the time of injection were 103.2 ± 38.3 and 117.8 ± 20.5 GBq/μmol, respectively. The radio-
chemical purities of these radioligands were greater than 99%.
Acquisition of images
All five subjects underwent two PET scans: first with 18F-FCWAY and second with 18F-Mefway.
For 18F-FCWAY PET, 500 mg of oral disulfiram was administered at 24 hours before the PET
scan to inhibit in vivo defluorination. Participants were instructed not to drink alcohol the day
before and 14 days after taking disulfiram [24]. After two months, 18F-Mefway PET scans were
performed without pretreatment with disulfiram. All brain PET images were acquired with an
integrated PET with computed tomography (PET/CT) scanner (Biograph 40 TruePoint PET/
CT, Siemens Healthcare, Knoxville, TN, USA). A head holder was applied to minimize head
movement, and brain CT images were acquired for attenuation correction (120 KeV, 180 mAs, 3
mm of slice thickness, 512 x 512 x 110 matrix with 0.67 x 0.67 x 2 mm of voxel size). After the
bolus injection of radiotracers for 1 minute (259.7 ± 23.7 MBq for 18F-FCWAY and 276.8 ± 29.2
MBq for 18F-Mefway), we acquired dynamic PET scans data for 2 hours. Then, 33 time frames
(6 x 30 sec, 3 x 1 min, 2 x 2 min, and 22 x 5 min) of attenuation-corrected dynamic PET images
were reconstructed in the same matrix and with same voxel size as the CT images by using the
ordered-subsets expectation maximization (OSEM) algorithm (iteration = 6 and subset = 16). In
all subjects, high resolution T1-weighted brain magnetic resonance (MR) images were acquired
in 1.5 T MR scanner (Signa Horizon, GEMedical Systems, Milwaukee, WI, USA) by using a fast
spoiled gradient echo sequence (matrix = 256 x 256 x 116 matrix, voxel size = 0.94 x 0.94 x 1.5
mm, repetition time = 8.5 ms, echo time = 1.8 ms, field of view = 240 mm, flip angle = 12o).
Fig 1. Chemical structures of 18F-FCWAY and 18F-Mefway.
doi:10.1371/journal.pone.0121342.g001
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Preprocessing of PET images
For motion correction, dynamic PET images were realigned to mean PET images except first
three time frames by sum of squared difference dissimilarity measure and Powell algorithm
(PMOD 3.1 software, PMOD Technologies Ltd., Adliswil, Switzerland). T1-weighed MR im-
ages were corrected for inhomogeneity and segmented into gray matter, white matter and cere-
brospinal fluid with statistical parametric mapping 8 (SPM8; The Wellcome Trust Centre for
Neuroimaging, University College London, UK) implemented in MATLAB 8 (MathWorks,
Natick, MA). The segments of gray and white matter were binarized with a threshold 0.5 to cre-
ate whole brain mask, and skull-stripped MR images were created by overlaying the whole
brain mask on inhomogeneity-corrected MR images. Mean PET images were coregistered to
the skull-stripped MR images. The dynamic PET images were spatially normalized to template
space by using the transformation parameter normalizing skull stripped MR images to the
skull-stripped Montreal Neurologic Institute (MNI) MR template. Finally, time-activity curves
(TACs) of seven cortical (frontal, parietal, occipital, temporal, insula, cingulate cortices, and
hippocampus) and two subcortical (striatum and cerebellum) regions were obtained by over-
laying template volumes of interest (VOI) modified from automated anatomical labeling
(AAL) template. For the cerebellum, the vermis was excluded from VOI since this area con-
tains small amount of 5-HT1A receptors [25]. The accumulation of radioactivity in skull caused
by the partial-volume effect was evaluated. To obtain exact TAC of skull, individual cranial
bone was extracted from CT image, and this mask for cranial bone was overlaid on individual
PET images. Regional TACs were normalized for the body weight and administrated dose and
converted to standardized uptake value (SUV) (radioactivity in kBq/cc x body weight in kg/in-
jected dose in MBq).
Kinetic analysis for binding values
We used cerebellar cortex without cerebellar vermis as reference tissue to obtain regional bind-
ing values. By using Ichise’s multilinear reference tissue model (MRTM), individual k2’ was ob-
tained from TAC of combined region (hippocampus and insula) with fixed time for the
linearization (t) at 60 minute [26]. Then with these parameters, regional distribution volume
ratio (DVR) values were calculated by using non-invasive Logan’s graphical analysis method
[27]. Parametric DVR images were created for visualization with same parameters and model.
Using 60 to 100 minute data, we also calculated regional area under the curve of TAC
(AUC) ratio (AUCtarget / AUCreference) with trapezoid method. Because the target-to-reference
ratios show the plateau in this period.
Statistical analysis
The Mann-Whitney U test was used to compare the DVR values between two radiotracers.
Pearson's correlation was used to determination of relationship between DVR and AUC ratio.
All statistical analyses were performed with Prism 5 (ver. 5.04, GraphPad).
Results
Comparison of skull uptake
The uptake of radioactivity in bone including skull is due to the presence of the radioactive
18F-fluoride ions resulting from metabolism of the parent compounds. The degree of radio-
fluorination can be used in the indicator for metabolic stability in vivo. In 18F-FCWAY PET,
skull uptake gradually increased to 1.44 ± 0.48 SUV at 30 minutes and decreased to 1.36 ± 0.40
SUV at 120 minutes. In contrast, the skull uptake of 18F-Mefway rapidly reached its peak at 1.5
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minutes (1.04 ± 0.21 SUV) and continuously decreased to 0.35 ± 0.02 SUV at 120 minutes
(Fig. 2). At 120 minutes, brain-to-skull ratio for 18F-Mefway PET in the combined regions of
insula and hippocampus was 1.58, which was similar to that for 18F-FCWAY PET (1.66).
Comparison of regional brain uptakes
The regional uptake patterns of both radiotracers were similar: from highest to lowest in follow-
ing order hippocampus, insula, temporal, frontal, cingulate, parietal, occipital cortices, striatum
and cerebellum (Figs. 3 and 4). However, regional peak SUV values for the 18F-FCWAY PET
are almost two fold than those of 18F-Mefway PET. In 18F-FCWAY PET, cortical uptake
Fig 2. Comparison of skull uptake in 18F-FCWAY and 18F-Mefway PET.Here, 18F-FCWAY PET data
were acquired with disulfiram pretreatment. Circles and error bars represent mean ± standard error of the
mean (SEM) in five healthy controls (closed circle = 18F-FCWAY, open circle = 18F-Mefway).
doi:10.1371/journal.pone.0121342.g002
Fig 3. Axial PET images of 18F-FCWAY (upper) and 18F-Mefway (lower). Time-averaged images using
dynamic PET images of 20–40, 60–80, and 80–100 minute, respectively.
doi:10.1371/journal.pone.0121342.g003
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continuously increased to 3.13 SUV at 30 minutes postinjection and slowly decreased (Fig. 4A).
In 18F-Mefway PET, the peak (1.6 SUV) appeared at 10 minutes, and the decline of radioactivity
was much faster than 18F-FCWAY (Fig. 4B). The cerebellar radioactivity of 18F-FCWAY was
2.5 times higher than that of 18F-Mefway (Fig. 5A). Target-to-reference ratio of 18F-FCWAY in
the combined region of insula and hippocampus is 37% higher than that of 18F-Mefway, and
this ratio for both radiotracers reached peudo-equilibrium after 60 minutes (Fig. 5B).
Comparison of regional binding values and parametric images
Regional DVR and AUC ratio values are summarized in Table 1 and Table A in S1 File. The
18F-FCWAY PET showed higher DVR and AUC ratio values than 18F-Mefway PET by 25–
63% and 23–57%, respectively. The AUC ratio values of both radiotracers strongly correlated
with DVR values (R2 = 0.97). However, the AUC ratio values were generally overestimated
compared to DVR values, and the regions with high density of 5-HT1A receptor tended to
show higher overestimation bias than those with low density of receptor. This overestimation
bias was greater for 18F-Mefway than 18F-FCWAY (Table 1 and Fig. 6). Similarly, parametric
DVR images of 18F-FCWAY PET showed higher DVR values than those of 18F-Mefway PET
(Fig. 7 and Fig. A in S1 File).
Fig 4. Regional time-activity curves of 18F-FCWAY (A) and 18F-Mefway (B) PET. Data represent mean
values for five healthy controls.
doi:10.1371/journal.pone.0121342.g004
Fig 5. Comparison of cerebellar uptake (A) and target-to-reference ratio (B) in the hippocampus
between 18F-FCWAY and 18F-Mefway PET. Circles and error bars represent mean ± standard error of the
mean (SEM) in five healthy controls (closed circle = 18F-FCWAY, open circle = 18F-Mefway).
doi:10.1371/journal.pone.0121342.g005
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Discussion
We found that the binding pattern of 18F-Mefway PET was similar to that of 18F-FCWAY PET
with disulfiram. Although lower brain uptake, lower binding values, and greater overestimation
bias of AUC ratio values of 18F-Mefway may be shortcomings of 18F-Mefway compared to
18F-FCWAY, the greatest advantage of 18F-Mefway was little skull uptake resulting from in vivo
defluorination. Thus, this radiotracer obviates the need for the use of disulfiram, a defluorination
blocker, which may be necessary for the 18F-FCWAY PET in order to obtain clean brain signals.
In addition, the radioactivity in the cerebellum for the 18F-Mefway PET was lower than that of
18F-FCWAY. Cerebellum is regarded as non-specific binding region because this area is almost
devoid of 5-HT1A receptors. The low cerebellar uptake gives rise to high contrast PET images re-
sults from the low background. This result is similar to the binding data in Table 2. Binding affin-
ity of 18F-Mefway showed the highest value, and the binding potential of 18F-Mefway was almost
two fold higher than the 18F-MPPF, same 18F-labeled radioligand for 5-HT1A receptor [28].
Therefore, 18F-Mefway may be a promising radioligand for 5-HT1A receptor imaging in human.
Table 1. Regional DVR and AUC ratio values for 18F-FCWAY and 18F-Mefway PET.
Regions 18F-FCWAY 18F-Mefway
DVR AUC ratio bias DVR AUC ratio bias
Frontal 3.27 ± 0.44 3.70 ± 0.45 0.12 2.00 ± 0.30‡ 2.36 ± 0.38 0.15
Parietal 2.95 ± 0.48 3.32 ± 0.50 0.11 1.80 ± 0.26‡ 2.11 ± 0.32 0.15
Occipital 2.53 ± 0.34 2.81 ± 0.34 0.10 1.63 ± 0.21‡ 1.87 ± 0.25 0.13
Temporal 3.93 ± 0.53 4.33 ± 0.48 0.09 2.42 ± 0.39‡ 2.98 ± 0.51 0.19
Cingulate 3.16 ± 0.63 3.62 ± 0.70 0.13 1.96 ± 0.39† 2.35 ± 0.42 0.17
Insula 4.32 ± 0.83 4.87 ± 0.78 0.11 2.63 ± 0.53‡ 3.26 ± 0.65 0.19
Hippocampus 4.60 ± 1.19 4.79 ± 0.66 0.04 3.06 ± 0.68 3.82 ± 0.82 0.20
Striatum 1.72 ± 0.46 1.84 ± 0.40 0.07 1.35 ± 0.23 1.50 ± 0.21 0.10
Data are presented as mean ± SD. Bias was calculated as (mean AUC ratio—mean DVR)/mean AUC ratio.
*P < 0.05,
†P< 0.01,
‡P< 0.001.
doi:10.1371/journal.pone.0121342.t001
Fig 6. Relationship between the DVR and AUC ratio values for 18F-FCWAY (A) and 18F-Mefway (B).
Dashed lines represent identity lines.
doi:10.1371/journal.pone.0121342.g006
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Reference method for kinetic modeling utilizes indirect input curves in the reference tissue
which is devoid of interesting receptors. Cerebellar gray matter and vermis contain noticeable
5-HT1A receptors whereas cerebellar white matter has few 5-HT1A receptors in humans [25].
Therefore we calculated regional binding values using the white matter as previously recom-
mended [29,30]
In the present study, the brain uptake values of 18F-Mefway PET were lower than those esti-
mated in the rhesus monkey [31]. This discrepancy may be partly explained by the species dif-
ferences in the enzyme system metabolizing the radiotracer and the substrate activity for P-gp.
First, cytochrome P450 (CYP) transforms lipophilic drugs into more polar compounds that
can be easily eliminated from the body [32]. The majority of CYP enzymes are conserved
Fig 7. Voxel-wise parametric mapping for 18F-FCWAY (A) and 18F-Mefway (B).
doi:10.1371/journal.pone.0121342.g007
Table 2. Comparison of the radiotracers for WAY-100635 derivatives.
Radiotracer Binding afﬁnitya(IC50, nM) Binding potential
Frontal Temporal Insula Cingulate Hippocampus
11C-WAY-100635b - 3.23 4.75 5.45 4.2 4.24
18F-MPPFc 3.66 0.61 0.85 0.96 0.75 1.43
18F-FCWAY 2.16 2.27 2.93 3.32 2.16 3.60
18F-Mefway 1.49 1.11 1.50 1.75 1.09 2.07
aIC50 measured in human recombinant 5-HT1A receptors expressed in Chinese hamster ovary cells by using
3H-WAY-100635 [28].
b, c Binding potential values for 11C-WAY-100635 and 18F-MPPF are calculated differently [37], [38].
For 18F-FCWAY and 18F-Mefway, binding potential values were calculated as DVR—1. DVR was a mean value in the various brain regions (this work).
doi:10.1371/journal.pone.0121342.t002
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among species but some isoforms of CYP were shown to generate species differences in drug
metabolism [33]. For instance, various CYP3A isoforms exist in difference species. CYP3A4,
3A5, 3A7 and 3A43 are the major drug-metabolizing isoforms for humans whereas CYP3A8 is
important for monkey. Second, P-gp is an efflux transporter located in the apical side of the en-
dothelial cell of the blood brain barrier (BBB) and plays a role in removal of potentially harmful
compounds such as toxic substances from the brain [34]. Similarly, the brain uptake of a radio-
tracer, which is a substrate for P-gp, can be affected by P-gp function. The 11C-(R)-RWAY and
18F-MPPF, 5-HT1A receptor antagonists, were found to be P-gp substrates in rodents and
showed low brain uptake [12,35]. Thus, it may be possible that the P-gp function partially con-
tributed to lower brain radioactivity of 18F-Mefway PET in this study. However, the interven-
tion of different CYP enzymes and P-gp merits further investigation.
Faster plasma clearance and slower tissue clearance increases the apparent volume of distri-
bution and target-to-reference ratio in transient equilibrium, and thus, this results in overesti-
mation bias compared to the total volume of distribution and DVR values derived from kinetic
modeling. Moreover, the overestimation bias is clearly affected by regional receptor density
[36]. In the present study, the AUC ratio values were higher than the DVR values for both ra-
diotracers, and the overestimation bias of AUC ratio values were higher for the 18F-Mefway
than 18F-FCWAY. The regional overestimation bias of 18F-Mefway was disproportional; high-
est in the hippocampus (20%) and lowest in the striatum (10%). AUC tissue to reference ratio
can easily applied to estimate the receptor binding to the target tissue. This large bias deduces
low accuracy of AUC ratio methods, therefore care should be taken for the large clinical studies
of 18F-Mefway PET with static PET scans.
Although defluorination and resulting high skull uptake is a major metabolic problem for
some 18F-labeled radioligands, there is no uniform, established method to prevent this issue.
The CYP2E1 and glutathione S-transferase are related with the defluorination of 18F-FCWAY
and 18F-SP203, respectively. Disulfiram, a direct CYP2E1 inhibitor, can be applied to prevent
defluorination in human [24]. Because of its known neurotoxicity particularly to the globus
pallidus, striatum, and substantia nigra and resulting extrapyramidal signs, its clinical applica-
tion may be limited [13,14]. Thus, little skull uptake 18F-Mefway even without defluorination
blocker is greatest advantage over 18F-FCWAY.
There are limitations in this study. First, we did not acquire plasma input function nor me-
tabolite assay, which might useful for fully analyzing the characteristics of 18F-Mefway. Second,
we did not correct the cerebellum for vascular radioactivity or uptake of labeled mebolites as
has been done with previous 18F-FCWAY studies. These factors may be causes for a moderate
decrease in target-to-reference ratios at the late times. Further studies should be necessary to
make these things clear.
Conclusion
Although the 18F-Mefway PET showed relatively low brain uptake and DVR values compared
to 18F-FCWAY PET with disulfiram pretreatment, 18F-Mefway has reasonable binding values
with little skull uptake. Therefore, 18F-Mefway may be a good candidate PET radioligand in
human use.
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